Not all patients with CLL have to have therapy. Regardless of all latest innovations, the iwCLL still suggests watchful observation for sufferers with asymptomatic illness.86 This recommendation is predicated on at least two randomized trials evaluating observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR